Literature DB >> 36264431

Emulation of the control cohort of a randomized controlled trial in pediatric kidney transplantation with Real-World Data from the CERTAIN Registry.

Christian Patry1, Lukas D Sauer2, Britta Höcker3, Burkhard Tönshoff3, Anja Sander2, Kai Krupka3, Alexander Fichtner3, Jolanda Brezinski2, Yvonne Geissbühler4, Elodie Aubrun4, Anna Grinienko5, Luca Dello Strologo6, Dieter Haffner7, Jun Oh8, Ryszard Grenda9, Lars Pape10, Rezan Topaloğlu11, Lutz T Weber12, Antonia Bouts13, Jon Jin Kim14, Agnieszka Prytula15, Jens König16, Mohan Shenoy17.   

Abstract

BACKGROUND: Randomized controlled trials in pediatric kidney transplantation are hampered by low incidence and prevalence of kidney failure in children. Real-World Data from patient registries could facilitate the conduct of clinical trials by substituting a control cohort. However, the emulation of a control cohort by registry data in pediatric kidney transplantation has not been investigated so far.
METHODS: In this multicenter comparative analysis, we emulated the control cohort (n = 54) of an RCT in pediatric kidney transplant patients (CRADLE trial; ClinicalTrials.gov NCT01544491) with data derived from the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry, using the same inclusion and exclusion criteria (CERTAIN cohort, n = 554).
RESULTS: Most baseline patient and transplant characteristics were well comparable between both cohorts. At year 1 posttransplant, a composite efficacy failure end point comprising biopsy-proven acute rejection, graft loss or death (5.8% ± 3.3% vs. 7.5% ± 1.1%, P = 0.33), and kidney function (72.5 ± 24.9 vs. 77.3 ± 24.2 mL/min/1.73 m2 P = 0.19) did not differ significantly between CRADLE and CERTAIN. Furthermore, the incidence and severity of BPAR (5.6% vs. 7.8%), the degree of proteinuria (20.2 ± 13.9 vs. 30.6 ± 58.4 g/mol, P = 0.15), and the key safety parameters such as occurrence of urinary tract infections (24.1% vs. 15.5%, P = 0.10) were well comparable.
CONCLUSIONS: In conclusion, usage of Real-World Data from patient registries such as CERTAIN to emulate the control cohort of an RCT is feasible and could facilitate the conduct of clinical trials in pediatric kidney transplantation. A higher resolution version of the Graphical abstract is available as Supplementary information.
© 2022. The Author(s).

Entities:  

Keywords:  Clinical trial design; Emulated cohorts; Pediatric kidney transplantation; Real-World Data

Year:  2022        PMID: 36264431      PMCID: PMC9584233          DOI: 10.1007/s00467-022-05777-x

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.651


  25 in total

1.  Body mass index percentiles for children and adolescents in Germany based on a nationally representative sample (KiGGS 2003-2006).

Authors:  A Schaffrath Rosario; B-M Kurth; H Stolzenberg; U Ellert; H Neuhauser
Journal:  Eur J Clin Nutr       Date:  2010-02-24       Impact factor: 4.016

Review 2.  Why randomized controlled trials do not always reflect reality.

Authors:  Kosmas I Paraskevas; Gert J de Borst; Frank J Veith
Journal:  J Vasc Surg       Date:  2019-03-14       Impact factor: 4.268

Review 3.  Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.

Authors:  Benjamin Speich; Belinda von Niederhäusern; Nadine Schur; Lars G Hemkens; Thomas Fürst; Neera Bhatnagar; Reem Alturki; Arnav Agarwal; Benjamin Kasenda; Christiane Pauli-Magnus; Matthias Schwenkglenks; Matthias Briel
Journal:  J Clin Epidemiol       Date:  2017-12-27       Impact factor: 6.437

4.  Real World Data and Evidence: Support for Drug Approval: Applications to Kidney Diseases.

Authors:  Aliza M Thompson; Mary Ross Southworth
Journal:  Clin J Am Soc Nephrol       Date:  2019-09-06       Impact factor: 8.237

Review 5.  Limitations of Randomized Clinical Trials.

Authors:  John B Kostis; Jeanne M Dobrzynski
Journal:  Am J Cardiol       Date:  2020-05-16       Impact factor: 2.778

6.  A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation.

Authors:  R Grenda; A Watson; K Vondrak; N J A Webb; J Beattie; M Fitzpatrick; M A Saleem; R Trompeter; D V Milford; N E Moghal; D Hughes; F Perner; S Friman; R Van Damme-Lombaerts; F Janssen
Journal:  Am J Transplant       Date:  2006-07       Impact factor: 8.086

7.  Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial.

Authors:  Burkhard Tönshoff; Robert Ettenger; Luca Dello Strologo; Stephen D Marks; Lars Pape; Helio Tedesco-Silva; Anna Bjerre; Martin Christian; Matthias Meier; El-Djouher Martzloff; Barbara Rauer; Jennifer Ng; Patricia Lopez
Journal:  Am J Transplant       Date:  2018-10-18       Impact factor: 8.086

8.  More comprehensive reporting of methods in studies using respondent driven sampling is required: a systematic review of the uptake of the STROBE-RDS guidelines.

Authors:  Lisa Avery; Michael Rotondi
Journal:  J Clin Epidemiol       Date:  2019-10-04       Impact factor: 6.437

9.  Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer's disease.

Authors:  Zhaoyi Chen; Hansi Zhang; Yi Guo; Thomas J George; Mattia Prosperi; William R Hogan; Zhe He; Elizabeth A Shenkman; Fei Wang; Jiang Bian
Journal:  NPJ Digit Med       Date:  2021-05-14

10.  Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records.

Authors:  Hun-Sung Kim; Suehyun Lee; Ju Han Kim
Journal:  J Korean Med Sci       Date:  2018-06-26       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.